干细胞来源的RPE细胞移植治疗视网膜退行性疾病的研究进展

Research progress of stem cell-derived RPE cell transplantation therapy for retinal degenerative diseases

在视网膜退行性疾病中,年龄相关性黄斑变性(agerelated macular degeneration,ARMD)和Stargardt黄斑营养不良(SMD)分别是威胁老年人和青少年人群视力最常见的疾病。目前仍缺乏可改善干性ARMD和Stargardt黄斑营养不良患者视力的确切疗法。近年来,干细胞(stem cells)技术不断发展,干细胞来源的RPE细胞移植疗法成为视网膜退行性疾病治疗的热点及新方向,本文将对该研究领域的最新研究进展作一综述。

Age-related macular degeneration（ARMD）and Stargardt＇s macular dystrophy（SMD）are two kinds of degenerative retinal diseases that respectively lead to irreversible vision loss of the elderly and juvenile population. However, the severe visual impairment in dry ARMD and SMD remains untreatable. In recent years, with the advancement of stem cell technology, stem cell-derived RPE cell transplantation therapy of retinal degeneration has become new research hotspot and direction. This article reviewed the progress of stem cell based approaches for treating retinal degenerative diseases and discussed the prospect and challenges in this field.